Information for "Switching for you to ocrelizumab inside RRMS individuals at risk of PML earlier given lengthy interval dosing of natalizumab"
From EECH Central
Basic information
Display title | Switching for you to ocrelizumab inside RRMS individuals at risk of PML earlier given lengthy interval dosing of natalizumab |
Default sort key | Switching for you to ocrelizumab inside RRMS individuals at risk of PML earlier given lengthy interval dosing of natalizumab |
Page length (in bytes) | 3,215 |
Page ID | 1449304 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Routevan44 (Talk | contribs) |
Date of page creation | 11:28, 7 May 2024 |
Latest editor | Routevan44 (Talk | contribs) |
Date of latest edit | 11:28, 7 May 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |